Publications by authors named "Jumoke Okikiolu"
Leuk Res Rep
December 2022
Article Synopsis
- Pegylated interferons, particularly peginterferon alfa-2a, are commonly used to treat Myeloproliferative Neoplasms (MPN), but a newer drug called ropeginterferon alfa-2b (ropegIFN) has emerged as an option, especially for Polycythaemia Vera (PV).
- RopegIFN received a recommendation from the European Medicine Authority (EMA) and FDA approval in November 2021 after positive results from Phase III trials.
- The study highlights the safety and tolerability of ropegIFN in MPN patients, confirming its efficacy in treating PV and its potential use during pregnancy.
